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Abstract 
Objective: To investigate the effect of nutrient stimulation of gut hormones by oligofructose 
supplementation on appetite, energy intake (EI), body weight (BW) and adiposity in overweight and 
obese volunteers. 
Methods: In a parallel, single-blind and placebo-controlled study, 22 healthy overweight and obese 
volunteers were randomly allocated to receive 30 g day-1 oligofructose or cellulose for 6 weeks 
following a 2-week run-in. Subjective appetite and side effect scores, breath hydrogen, serum short 
chain fatty acids (SCFAs), plasma gut hormones, glucose and insulin concentrations, EI, BW and 
adiposity were quantified at baseline and post-supplementation. 
Results: Oligofructose increased breath hydrogen (P<0.0001), late acetate concentrations (P=0.024), 
tended to increase total area under the curve (tAUC)420mins peptide YY (PYY) (P=0.056) and reduced 
tAUC450mins hunger (P=0.034) and motivation to eat (P=0.013) when compared with cellulose. 
However, there was no significant difference between the groups in other parameters although 
within group analyses showed an increase in glucagon-like peptide 1 (GLP-1) (P=0.006) in the 
cellulose group and a decrease in EI during ad libitum meal in both groups. 
Conclusions: Oligofructose increased plasma PYY concentrations and suppressed appetite, while 
cellulose increased GLP-1 concentrations. EI decreased in both groups. However, these positive 




Obesity is associated with numerous comorbidities including type 2 diabetes, cardiovascular disease 
and cancers (1). Dietary components that promote satiety and suppress energy intake could offer a 
public health solution to weight gain in adults. Certain dietary fibers have beneficial effects in 
modulating food intake and body weight (BW) (2,3). We and others have shown that inulin-type 
fructans supplementation can stimulate the release of anorectic gut hormones which is related to 
reduced appetite (4) and energy intake (5) in humans. The mechanisms behind these observations 
are unclear, but may be due to increased colonic fermentation resulting in greater production of 
short chain fatty acids (SCFAs). SCFAs are thought to modulate appetite by binding to their 
receptors, free fatty acid receptors 2 and 3 (6,7) triggering colonic L-cells to release anorectic gut 
hormones, including GLP-1 and PYY (8-10). 
 
Oligofuctose is a fermentable carbohydrate, which is known to affect appetite (5,11), however it is 
unclear whether this effect is due to its fermentation in the gut or other large bowel effects. To date, 
there have been no studies directly compared the effect of oligofructose on energy regulation with 
an inert dietary fiber. Indeed, in previous studies oligofructose has been compared to maltodextrin, 
an absorbable carbohydrate as a control (5,11-13). Little is known regarding the effects of 
oligofructose supplementation on body fat distribution and in particular ectopic fat content in 
humans. In rodents, we and others have demonstrated a consistent reduction in visceral adipose 
tissue (AT) and liver fat (14,15). This is of interest as increased visceral AT and liver fat accumulation 
have been associated with metabolic disturbances, including insulin resistance, hypertension and 
diabetes independent of BW (16,17). 
 
Previous studies looking at the effects of oligofructose supplementation on body composition did 
showed a significant reduction in BW in adults (12) and total fat mass in adolescents (18) when 
compared to control. However, these studies have employed dual energy X-ray absorptiometry, 
which does not allow direct measurement of individual fat depots. 
 
Therefore, in this 8-week supplementation study, we investigated the role of oligofructose 
compared to a nonfermentable fiber, cellulose on gut hormone concentrations, appetite, energy 
intake and assessed changes in total and regional body fat content using magnetic resonance 




All volunteers gave informed consent prior to the start of the study. The study protocol was 
approved by the Hounslow and Hillingdon Research Ethics Committee (project registration number: 
09/H0709/18) (Clinical trial number: NCT00912197) and carried out in accordance with the 
Declaration of Helsinki. Eligibility criteria included healthy adults with a BMI in the range 25-35 
kg/m2, aged 20-50 years, and non-smokers. Emotional, external and restraint scores were assessed 
using the Dutch Eating Behaviour Questionnaire. Exclusion criteria included chronic diseases, 
gastrointestinal disease, pregnancy or breastfeeding, any medication, unstable BW within the 3 
months before the study, an excessive diet or physical activity regime, ingestion of prebiotic or 
probiotic products>three times per week, and dietary fiber intakes >25 g day-1. The recruited 
volunteers were randomly assigned to the oligofructose or cellulose supplementation using an 
envelope system based on sex and gender by a member of the department who was not directly 
involved in this study.  
 
Dietary fiber supplements 
Oligofructose (BeneoTM P95: Orafti, Tienen, Belgium) and cellulose were provided as white, 
powdered supplements in sachets each containing 10 g dietary fiber. Maltodextrin was added to the 
cellulose supplement to make the two supplements isoenergetic (47.4 kcal/198.6 kJ per 30 g fiber 
supplementation). Volunteers were instructed to take the supplement with their main meals. 
 
Study protocol 
The study design is summarized in Supporting Information Figure S1A. This was a randomized, 
parallel, single-blinded, controlled study. Volunteers attended five study visits, three visits for 
appetite measurements [Visits 1 (acclimatization visit to familiarize subjects with the study 
procedures), 3 (day 0) and 4 (day 56)] and two visits for MRI total body scans (visits 2 and 5). The 8-
week supplementation period took place between visits 3 and 4 and included a 2-week run-in period 
to allow the bowel to adapt to the 30 g of dietary fiber. 
 
Appetite study day 
On each study visit, weight was measured prior to the start of the study. Subjective appetite and 
side effect ratings [assessed by visual analogue scales (VAS) (19)], breath hydrogen and blood 
samples were obtained from volunteers throughout the study session. Standardized breakfast and 
lunch meals were served at 0 and 240 min, respectively. Energy intake was assessed at an ad libitum 
meal at 420 min using a homogenous pasta or rice based meal (each volunteer had the same meal 
on each occasion). Volunteers were instructed to eat until comfortably full and were left alone and 
undisturbed whilst eating. Food and water were weighed before and after the assessment. On post-
supplementation visit (day 56), 30 g of the fiber supplements were split into two equal portions and 
added to the fruit juice, which accompanied the breakfast and lunch meals. The appetite study 
protocol is summarized in Supporting Information Figure S1B. 
 
Estimation of colonic fermentation 
Colonic fermentation activity was estimated by measuring breath hydrogen using a portable hand-
held monitor (Gastrolyzer, Bedfont Scientific, Kent, UK). 
 
Blood sampling 
A cannula was inserted in a forearm vein for collection of venous blood samples throughout the 
three study days. Blood for gut hormone analyses was collected into potassium EDTA tubes 
containing aprotinin (Trasylol, Bayer, Newbury, UK). Blood samples were centrifuged at 3000g at 4°C 
for 10 min, separated into plasma or serum and stored at -80°C until analyzed. 
 
Free-living appetite and energy intake assessment 
To estimate the impact of the supplementation in the home environment we assessed appetite 
sensations by VAS and energy intake by 7-day food diary at baseline and the last week of the 
supplementation period. Food diaries were analyzed using Dietplan6 (Forestfield Software, West 
Sussex, UK). During the supplementation, volunteers were contacted by investigators by phone 
every 2 weeks. Compliance was monitored by assessing unused sachets returned by volunteers at 
the end of the study. 
 
Biochemistry 
Total PYY and GLP-1 concentrations were quantified using specific and sensitive in-house 
radioimmunoassays as previously described (20,21). Plasma insulin concentrations were assayed 
using RIA kits (Millipore, MO). The sensitivity concentrations for PYY, GLP-1 and insulin were 2.5 
pmol l-1, 7.5 pmol l-1, and 1.4 µU ml-1, respectively. The intraassay variations were 4.1, 3.3, and 7.6%, 
respectively. Glucose, fasting insulin, cholesterol, triglycerides, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), and gamma-glutamyltranspeptidase (γGT) were analyzed in the 
Department of Clinical Biochemistry, Hammersmith Hospital, London using an Abbott Architect 
ci8200 analyzer (Abbott Diagnostics, Maidenhead, UK). Fasting glucose and insulin were used to 
calculate HOMA-IR and β-cell function (%B) (22). 
 
Serum SCFA measurement 
Serum SCFA concentrations at 0, 300, and 450 min were measured by gas chromatography modified 
from previously described methods (23,24). See Supporting Information for details. 
 
MRI study days 
Total and regional body composition and anthropometry (weight, height, waist and hip 
circumferences) were measured. BMI and waist:hip ratio (WHR) were then calculated. Blood for 
biochemical measurements were obtained after 12-h overnight fast.  
 
MRI whole body and regional adipose tissue content 
Rapid T1-weighted magnetic resonance images were obtained using a 1.5T Phillips Achiva scanner 
(Phillips, Best, the Netherlands), as described previously (25) (see Supporting Information). 
Intrahepatocellular lipids (IHCL) and pancreatic fat were measured relative to liver water content, as 
previously described (26). Soleus and tibialis IMCL lipid concentrations were measured relative to 
total muscle creatine signal, as previously described (27). 
 
Statistical analyses 
Data are presented as mean ± standard error (SEM) unless otherwise stated. The sample size was 
based on power calculations that used plasma PYY concentrations as a primary outcome (4). With 
the estimated increase of tAUC480mins PYY of 5234±3638 ρmol min-1 (mean±SD) based on 0.8 power to 
detect a significant difference (P=0.05, two tailed), a minimum of 18 participants were needed. To 
allow for dropouts, 28 volunteers were recruited. Data were checked for Gaussian distribution using 
D’Agostino & Pearson omnibus normality test. Nonparametric data were log transformed and 
geometric means with 95% confidence interval are reported. Analysis of covariance (ANCOVA) with 
baseline values, age, BMI, and gender as covariates was used to compare oligofructose and cellulose 
treatments. Within group effects were assessed using two-tailed paired t test if normally distributed 
and Wilcoxon signed-ranks test if the data was non-parametric. Significance was assumed as P<0.05. 
Analyses were performed using GraphPad Prism Version 5.0 (GraphPad Software, San Diego, CA) and 




A total of 28 volunteers were recruited, 22 volunteers completed the study. Six volunteers withdrew 
from the study due to work and personal reasons unrelated to the supplementation. Baseline 
characteristics of the 22 volunteers are described in Table 1. 
 
Supplementation compliance 
Four volunteers reported side effects such as bloating, flatulence or stomach discomfort during 
week 3 and 4, and were allowed to continue taking two sachets per day (20 g) during this time. 
However, they managed to consume 30 g day-1 fiber in week 5 and 6. This resulted in a compliance 
in the range of 60-77% in these four volunteers whilst the remaining volunteers had compliance 
rates between 86 and 100% leading to an overall group compliance rate of 89.8%±13.1% in the 
oligofructose group (n=12) and 89.7%±12.8% in the cellulose group (n=10). 
 
Anthropometry 
No significant differences were observed in any of the anthropometric measurements before or 
after the intervention (Table 1). 
 
Breath hydrogen secretion 
Oligofructose significantly increased breath hydrogen concentration compared to cellulose (P=0.001) 
(Figure 1), with a three-fold increase in tAUC450mins from baseline in the oligofructose group whilst 
there was no significant effect of tAUC450mins within the cellulose group (P=0.435). 
 
Serum SCFA analysis 
Oligofructose significantly increased acetate concentrations at 450 min (P=0.024) and showed a 
tendency to increase acetate concentration at 300 min (P=0.077) compared with cellulose. In 
addition, within group analysis demonstrated that oligofructose significantly increased fasting serum 
propionate (P=0.019) and butyrate (P=0.034) concentrations and tended to increase tAUC450mins 
butyrate (P=0.073) compared to baseline. In contrast, intake of cellulose significantly reduced 
acetate concentration at 300 min (P=0.012) and tAUC450mins (P=0.030) compared to baseline. 
 
Hormone and glucose responses 
Oligofructose significantly increased AUC300-420mins PYY (P=0.042) and tended to increase tAUC420mins 
PYY (P=0.056) when compared to cellulose (Figure 2A). In contrast, oligofructose had no significant 
impact on GLP-1 concentration when compared to cellulose (P=0.327) (Figure 2B). Similarly, fasting 
plasma PYY and GLP-1 concentrations were also not significantly affected by treatments (P=0.799, 
P=0.823, respectively). Nevertheless, within group analysis showed that cellulose significantly 
increased GLP-1 tAUC420mins, AUC0-300mins and AUC300-420mins (P=0.006, P=0.021, and P50.006, 
respectively) compared to baseline. Oligofructose also significantly increased GLP-1 AUC0-300mins 
(P=0.042) compared to baseline. 
 
There was no significant difference in glucose responses between oligofructose and cellulose 
treatments (P=0.744) (Figure 2C). However, oligofructose has a tendency to increase tAUC420mins and 
tAUC300-420mins glucose response when compared to the baseline (P=0.059 and P=0.062, respectively), 
whilst no significant effect was found within cellulose group (P=0.993). There was no significant 
difference in tAUC420mins insulin between treatment (P=0.990) or within groups (P=0.512 and P=0.943 
for oligofructose and cellulose, respectively) (Figure 2D). 
 
Energy intake assessments 
No significant difference in energy intake at the ad libitum meal was observed between groups 
(P=0.578). However, oligofructose significantly reduced energy intake compared to baseline 
(873.16±54.06 kcal to 760.19±51.59 kcal, 12.9% reduction, P=0.007) with a similar trend in the 
cellulose group (867.61±159.45 kcal to 725.34±117.40, 16.4% reduction, P=0.05). 
 
Food diary analyses showed no significant change in energy intake between groups (P = 0.821) or 
within oligofructose or cellulose groups (P=0.522 and P=0.652, respectively).Two volunteers were 
under-reporters. However, omitting these volunteers from the analysis did not reveal any effect of 
treatments on energy intake (P>0.05). No significant effects of treatments on macronutrient or fiber 
(without supplementation) intakes were found (P>0.05) (data not included). 
 
Appetite sensation ratings 
Oligofructose significantly reduced hunger (P=0.034), motivation to eat (P=0.013) and desire to eat 
savoury food (P=0.003), fatty food (P=0.013) and salty food (P=0.009), but did not have a significant 
effect on fullness scores (P=0.493) when compared to cellulose (Table 3). There was no significant 
difference between treatments (P=0.135) in appetite sensation assessment during home 
supplementation, although there was a trend toward a reduction in hunger scores within the 
oligofructose group (P=0.054).  
 
Gastrointestinal side effect assessments 
On the appetite study day, oligofructose increased flatulence (P=0.005) and bloating scores 
(P=0.007) when compared to cellulose whilst no significant effect of treatments on gastrointestinal 
side effect scores was demonstrated during home supplementation (Table 3). 
 
Total and regional adipose tissue content 
Total and regional AT content were not affected by the treatments (Table 4). However, there was a 
trend for an increase of internal AT in the oligofructose group although these changes did not reach 
significance (P=0.065). Similarly, intra-abdominal AT (IAAT) within oligofructose group was 
significantly increased (P=0.043) after the supplementation, although the percentage difference 
between the groups was not significant (P=0.257). 
 
MRS of liver, muscle, and pancreas fat 
The 1H MRS of liver, muscle and pancreas fat results are shown in Table 4. No significant differences 
were observed in any on the ectopic fat depots measured. 
 
Biochemical analysis 
No significant differences were found in any of the biochemical measurements (AST, ALT, γGT, 
glucose, insulin, HOMA-IR, HOMA % B and lipid profiles) (Supporting Information Table S1). 
  
Discussion 
The effects of fermentable carbohydrates, such as oligofructose, on appetite and adiposity in 
humans are poorly understood. In this study, we evaluated the effect of 8 weeks high dose 
oligofructose supplementation on gut hormones, appetite, weight loss, and body fat distribution. 
The current study confirmed the results of previous studies, that oligofructose significantly reduces 
subjective hunger, increases breath hydrogen (5,11) and plasma PYY concentrations (12,13). 
However, energy intake at ad libitum meal in the oligofructose group was not significantly different 
from the cellulose group although it was decreased within the groups. There was also no effect of 
treatment on BW and overall body fat content. In this study we controlled for material entering the 
colon by giving cellulose, a nonfermentable fiber source which did not increase breath hydrogen 
suggesting minimal fermentation. Surprisingly, we did observe an increase in GLP-1 concentration 
and a decrease in food intake in the cellulose group, suggesting despite the apparent inert nature of 
cellulose, it has an effect on GLP-1 release. Insoluble fiber like cellulose potentially stimulates GLP-1 
secretion by increasing the time it takes fiber to reach the distal small intestine (28). However, this 
increase did not make an impact on insulin release. This raises the possibility that the two fibers 
have different effects on gut hormones. 
 
Rodent studies suggest that stimulation of colonic fermentation by inulin-type fructans increase GLP-
17-36 and PYY release from the intestinal L-cells (8,29). In our study, intake of oligofructose led to a 3-
fold increase in breath hydrogen concentrations, a marker of colonic fermentation, and a significant 
increase in serum SCFAs. These observations were associated with a significant increase in 
PYY, but no significant modulation in GLP-1. There are conflicting reports regarding the effect of 
oligofructose on circulating GLP-1 concentrations in human studies; some have shown that 
oligofructose significantly increases GLP-1 concentrations (11,13,30) whilst others did not (4,12). It 
may be that fermentation of inulin-type fructans in the human colon causes a differential release of 
PYY. 
 
The increase in breath hydrogen, SCFAs and PYY also coincided with increases in fullness and 
decreases in hunger, motivation to eat and energy intake at the ad libitum meal. However, this was 
not translated into an effect on BW. This may be due to hedonic drive to maintain energy 
homeostasis in the long term overriding the anorectic signals from the gut hormones. It is possible 
that although oligofructose significantly raised plasma PYY concentrations, they did not reach the 
level of plasma concentrations observed following PYY infusions which resulted in a significant 
decrease in food intake [current study peak concentration 40 pmol l-1 vs. 60 pmol l-1 (31)]. 
Previous studies have compared oligofructose to readily digestible carbohydrates (maltodextrin) 
(5,11-13). In this study, we aimed to evaluate the effect of oligofructose when compared to 
cellulose, a different fiber. Cellulose mainly acts as a bulking agent (32). However, recent reports 
suggest that it can be fermented by gut microbiota, but to a much lesser extent than oligofructose 
(33). However, despite the different physicochemical properties of cellulose and oligofructose, they 
may have promoted satiety signals at different parts of the gut, thus resulting in little or no 
difference in effects on appetite, BW and body fat between the treatments. 
 
Previous studies using oligofructose as a dietary supplement have shown a reduction in BW and 
overall body fat content when compared to control treatments (12,18). However, body fat in these 
studies was only reported as a total adiposity and therefore the role of oligofructose on body fat 
distribution (total, abdominal, and regional adiposity) remains unclear. In the present study, 
oligofructose supplementation had no significant effect on total body fat content or BW when 
compared to cellulose. Overall, it appeared that oligofructose altered body fat distribution, whilst 
only IAAT achieved significance, there was a consistent trend for an increase in internal body fat 
stores following OFS supplementation. This is at odds with previous rodent studies which have 
reported reduced internal fat in similar interventions. Although oligofructose had no significant 
effect on ectopic fat content compared with cellulose, our investigation showed a tendency to 
reduce IHCL within the oligofructose group. However, both groups had mean baseline IHCL 
concentrations within the normal range (34), making it more difficult to achieve a significant 
reduction in what were already relatively low levels of liver fat. This may also in part explain why no 
significant changes in biochemical markers of liver function (AST, ALT, and cGT concentrations) were 
found in this study. Additionally, lack of change in ectopic fat accumulation in either the soleus and 
tibialis muscles or pancreas could possibly be related to no change in HOMA-IR and HOMA-B, 
biomarkers for insulin resistance. 
 
The nonsignificant changes in body fat content and distribution in the current study may reflect the 
relatively small sample size, giving us insufficient power to detect subtle differences between 
treatments. Furthermore, the 8-week period of supplementation may not be long enough for 
oligofructose to exert its effects despite the relatively high dose of 30 g oligofructose. Indeed, other 
short term studies on fermentable carbohydrates have reported similar negative results (35,36). 
Thus, it is possible that fermentable fibers need a longer period of supplementation to affect BW 
and body fat.  
 
In summary, the results of this study suggest that oligofructose potentially has a short term effect on 
appetite possibly modulated through colonic fermentation and the anorectic gut hormone, PYY. 
Although not significant, the slightly reduced IHCL and cGT concentrations from baseline may 
suggest that the beneficial effect of oligofructose supplementation perhaps is by protecting the liver 
against fat accumulation. However, the increases observed in internal fat depots suggest that future 
studies would be needed to determine whether any beneficial changes to appetite outweigh 
possible negative changes in body fat distribution. Also, we report that the control cellulose increase 
GLP-1 release without a measurable increase in fermentation. 
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TABLE 1: Volunteers characteristics at baseline and anthropometric measurements at baseline and post-
supplementationa.   
aData are expressed in means ± SEM. 
 bTest for difference between groups for baseline measurement was performed by unpaired t-test. 
cTest for difference between groups were conducted by ANCOVA, with baseline, age and gender as covariates, 





 Oligofructose  Cellulose  P value 
 (n=12) Range  (n=10) Range   
Females/males (n)  9/3 -  7/3 -  - 
Age (y)  36.5 ± 2.2 21 - 49  28.7 ± 2.3 20 - 47  0.025b 
Emotional score  2.3 ± 0.4 1.0 – 4.8  2.0 ± 0.2 1.3 – 2.9  0.830b 
External score  2.9 ± 0.2 1.5 – 4.1  2.7 ± 0.2 1.5 – 4.1  0.625b 
Restraint score  2.1 ± 0.2 1.2 – 3.1  2.2 ± 0.2 1.2 – 3.1  0.647b 
BW (kg) (day 0)  83.7 ± 4.9 59.4 – 121.2  86.0 ± 4.4 65.9 – 106.4  0.742b 
BW (kg) (day 56)  84.1 ± 4.8 58.7 – 117.5  86.3 ± 4.5 66.3 – 108.2   0.715c 
BMI (kg/m2) (day 0)  29.7 ± 1.0 25.0 – 34.6  31.1 ± 1.1 26.0 – 35.0  0.364b 
BMI (kg/m2) (day 56)  29.9 ± 1.1 24.8 – 35.0  31.2 ± 1.1 25.8 – 35.0  0.715c 
WHR (day 0)  0.86 ± 0.03 0.68 – 1.0  0.82 ± 0.02 0.73 – 0.94  0.270b 
WHR (day 56)  0.88 ± 0.02 0.77 – 0.98  0.83 ± 0.03 0.75 – 0.98  0.521c 
TABLE 2: SCFA concentrations and tAUC450mins measured on the baseline (Day 0) and post-supplementation (Day 56) appetite study day 1 
Type of SCFA Timepoint 
(mins) 
Oligofructose (n=12)  Cellulose (n=10) 
Day 0 Day 56  Day 0 Day 56 
       
Total fasting µM 0 82.6 ± 2.2 83.7 ± 2.0  80.7 ± 3.1 83.4 ± 2.9 
Total postprandial µM 300 87.0 ± 2.2 89.2 ± 2.1  91.4 ± 3.4 84.6 ± 2.9 
µM 450 82.4 ± 2.5 85.6 ± 2.4  79.9 ± 2.6 77.8 ± 2.2 




0  77.4 ± 1.8 77.3 ± 5.8  75.0 ± 2.9 77.5 ± 2.5 
300 81.1 ± 2.0 83.7 ± 2.1  85.2 ± 3.2 78.6 ± 2.6b 
450 76.8 ± 2.5 81.3 ± 2.1c  75.1 ± 2.4 72.8 ± 1.8 




0 4.8 ± 0.5 5.4 ± 0.6b  5.1 ± 0.6 5.0 ± 0.5 
300 5.3 ± 0.5 5.4 ± 0.6  5.2 ± 0.6 5.2 ± 0.5 
450 5.3 ± 0.5 5.4 ± 0.6  5.1 ± 0.5 5.4 ± 0.6 




0 0.4 ± 0.1 0.8 ± 0.1b  0.6 ± 0.2 0.9 ± 0.1 
300 0.6 ± 0.1 0.8 ± 0.1  0.9 ± 0.1 0.8 ± 0.2 
450 0.5 ± 0.1 0.9 ± 0.1  0.5 ± 0.2 0.7 ± 0.2 
µM x min tAUC 242.6 ± 29.4 340.8 ± 42.4  323.4 ± 52.2 358.2 ± 53.1 
        
aData are expressed in means ± SEM  
b Significantly different from Day 0, *P< 0.05  
cSignificantly different from cellulose group, *P< 0.05  
  
TABLE 3: Subjective appetite sensations measured on the baseline (Day 0) and post-supplementation (Day 56) appetite study day and supplementation 
period, baseline (Day -8 to -1) and during supplementation (Day 49 -55)a 
 Oligofructose (n=12)  Cellulose (n=10) P Valueb 
Appetite sensation Day 0 Day 56  Day 0 Day 56 
Appetite study day       
Hunger (cm min) 2053.9 ± 308.7 1387.3 ± 263.2c  1850.6 ± 395.3 1838.6 ± 315.9 0.034 
Fullness (cm min) 1790.8 ± 243.7 2095.3 ± 249.3c  1615.1 ± 314.5 1805.3 ± 254.7 0.493 
Motivation to eat (cm min) 2059.6 ± 294.5 1412.5 ± 229.2c  1946.4 ± 367.6 1847.4 ± 313.4 0.013 
Desire to eat sweet food (cm min) 1759.5 ± 372.2 1232.8 ± 361.3c  2022.8 ± 444.9 1904.3 ± 364.1 0.342 
Desire to eat savoury food (cm min) 1658.0 ± 365.3 1090.6 ± 251.1c  1534.7 ± 445.3 1757.7 ± 420.0 0.003 
Desire to eat fatty food (cm min) 1401.9 ± 324.8 566.3 ± 191.2c  1022.4 ± 380.8 1092.5 ± 320.9 0.013 
Desire to eat salty food (cm min) 1617.4 ± 369.6 880.8 ± 238.8c  1035.7 ± 350.6 1322.0 ± 341.4 0.009 
Bloating (cm min)d 15.1 (1.0 – 218.6) 51.6 (2.7 – 985.8)c  105.2 (21.6 – 512.8) 14.1 (0.6 – 363.4) 0.007 
Stomach discomfort (cm min)d 72.6 (19.4 – 271.5) 4.0 (0.2 – 75.4)c  43.3 (11.6 – 161.0) 10.6 (1.1 – 106.1) 0.011 
Flatulence (cm min)d 11.1 (0.9 – 132.4) 57.6 (7.0 – 470.5)c  32.8 (3.8 – 280.5) 5.9 (0.4 – 99.1) 0.005 
Diarrhoea (cm min)d 1.2 (0.1 – 9.8) 0.5 (0.1 – 3.9)  5.1 (1.1 – 24.0) 0.5 (0.1 – 5.1)b 0.896 
Sickness (cm min)d 14.4 (2.5 – 81.8) 1.9 (0.2 – 20.9)c  19.4 (5.6 – 67.8) 2.4 (0.2 – 37.9) 0.613 
       
Home supplementation period       
Hunger (cm) 4.8 ± 0.9 3.6 ± 0.8  3.6 ± 0.8 4.1 ± 0.6 0.135 
Fullness (cm) 4.7 ± 0.5 4.2 ± 0.8  4.2 ± 0.8 4.1 ± 0.6 0.688 
Bloating (cm)d 0.9 (0.2 – 1.5) 2.3 (0.6 – 3.9)  0.4 (0.1 – 1.2) 0.4 (0.1 – 1.2) 0.974 
Stomach discomfort (cm)d 0.5 (0.2 – 1.2) 0.4 (0.1 – 1.2)  0.2 (0.1 – 0.8) 0.2 (0.1 – 0.8) 0.868 
Flatulence (cm)d 0.9 (0.4 – 1.5) 1.7 (0.3 – 3.2)  0.3 (0.1 – 1.1) 0.3 (0.1 – 1.3) 0.224 
Diarrhoea (cm)d 0.1 (0.04 – 0.2) 0.1 (0.04 – 0.5)  0.01 (0.03 – 0.3) 0.1 (0.04 – 0.4) 0.837 
Sickness (cm)d 0.1 (0.05 – 0.3) 0.1 (0.05 – 0.4)  0.1 (0.04 – 0.4) 0.2 (0.04 – 0.6) 0.760 
aData are expressed in means ± SEM for normal distribution and geometric mean (95% confidence interval) for non-normally distributed data  
b Significantly different from Day 0, *P< 0.05 (Paired t-test)  
cTest for difference between groups were conducted by ANCOVA, with baseline, age and gender as covariates, *P< 0.05  
dData analysis was performed on log transformed values. Values presented as anti-log of the mean of log-transformed values.
TABLE 4: Total and regional body adipose tissue before and after intervention in the treatment 
groupsa 
AT (L)  Group  Pre Post P valueb 
TAT  OFS 36.3±2.8 37.0±2.8 0.858 
 CEL 38.4±3.7 38.7±3.8  
SAT OFS 30.4±2.7 30.6±2.7 0.914 
 CEL 33.8±3.4 34.1±3.4  
IAT OFS 5.9±0.8 6.4±0.8 0.489 
 CEL 4.6±0.4 4.5±0.5  
IHCLc OFS 1.9 (0.6-6.0) 1.4 (0.4-4.9) 0.814 
 CEL 0.7 (0.4-1.2) 0.6 (0.3-1.1)  
S-IMCLc OFS 10.7 (6.8-17.0) 12.0 (8.1-18.1 0.883 
 CEL 12.6 (7.2-22.1) 12.0 (7.4-19.2)  
T-IMCL OFS 7.2±1.0 6.5±1.1 0.366 
 CEL 7.0±0.9 7.1±0.8  
Pancreasc OFS 2.9 (2.0-4.0) 2.8 (1.8-4.2) 0.719 
 CEL 1.6 (1.1-2.3) 1.8 (1.3-2.4)  
ASAT OFS 9.5±1.0 9.5±1.0 0.194 
 CEL 10.2±1.1 10.4±1.2  
NASAT OFS 20.9±1.8 21.1±1.8 0.753 
 CEL 23.6±2.4 23.7±2.4  
IAAT OFS 3.1±0.5 3.3±0.5 0.257 
 CEL 2.1±0.2 2.1±0.3  
NAIATc OFS 2.7 (2.1-3.4) 2.9 (2.3-3.7) 0.308 
 CEL 2.4 (2.0-3.0) 2.3 (1.8-3.0)  
IAT:SAT ratioc OFS 0.2 (0.1-0.3) 0.2 (0.1-0.3) 0.263 
 CEL 0.1 (0.1-0.2) 0.1 (0.1-0.2)  
IAAT:ASAT ratioc OFS 0.3 (0.2-0.5) 0.3 (0.2-0.5) 0.794 
 CEL 0.2 (0.2-0.3) 0.2 (0.1-0.3)  
aData are expressed in Mean6SEM for normally distributed and geometric mean (95% confidence 
interval) for non-normally distributed.  
bDifference between groups were analysed by ANCOVA, with baseline, age and gender as covariates, 
*P<0.05. 
cData were log transformed for analysis. 
Abbreviations: ASAT: abdominal subcutaneous adipose tissue, CEL: cellulose group (n510), IAAT: 
intra-abdominal adipose tissue, IAT: internal adipose tissue, IHCL: intrahepatocellularlipid, NAIAT: 
non-abdominal internal adipose tissue,NASAT: nonabdominal subcutaneous adipose 
tissue,OFS:oligofructose group (n512), SAT: subcutaneous adipose tissue, S-IMCL: soleus-
intramyocellular lipid, TAT: total adipose tissue, T-IMCL: tibialis-intramyocellular lipid.  
 Figure Captions 
Figure 1: Mean (± SEM) (ppm) and tAUC450min (ppm*min) of breath hydrogen concentrations on appetite 
study day at baseline (day 0) and post-supplementation (day 56), oligofructose (n=12) and cellulose  
n=10).  Inset: the tAUC450mins breath hydrogen concentrations in the oligofructose group was significantly 
higher compared to cellulose group on post-supplementation day (P = 0.001, ANCOVA). 
 
Figure 2: Mean (± SEM) concentrations and tAUC420mins of plasma total peptide YY (PYY) (A), total  
glucagon-like-peptide 1 (GLP-1) (B), glucose (C) and insulin (D) on appetite study day at baseline (day 0) 
and following oligofructose and cellulose supplementation on post-supplementation (day 56), 
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